Specifically, OXPHOS blockade markedly reduced activation of TGFβ and MAPK pathways and reversed EMT phenotypes in breast cancer cells undergoing osteogenic differentiation (Hu et al., 2020). This evidence concerns the gene TGFB1 and breast cancer.